Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC)

Enzalutamide, a nonsteroidal second-generation antiandrogen, has been recently approved for the management of castration-resistant prostate cancer (CRPC). Although patients can benefit from enzalutamide at the beginning of this therapy, acquired enzalutamide resistance usually occurs within a short...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Biol Chem
Autors principals: Kong, Yifan, Cheng, Lijun, Mao, Fengyi, Zhang, Zhuangzhuang, Zhang, Yanquan, Farah, Elia, Bosler, Jacob, Bai, Yunfeng, Ahmad, Nihal, Kuang, Shihuan, Li, Lang, Liu, Xiaoqi
Format: Artigo
Idioma:Inglês
Publicat: American Society for Biochemistry and Molecular Biology 2018
Matèries:
Cell Biology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6139550/
https://ncbi.nlm.nih.gov/pubmed/30089652
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1074/jbc.RA118.004442
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars